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risen because the crop is used for fuel production. There is no 
such problem with algae (though some species are used as 
animal fodder).
Food production and algae nurseries are not incompatible. 
As Professor de Baar explains, ‘A big container would have to 
be transparent to allow sunlight to enter. It could be a vertical 
container of several metres high, which would be aerated with 
air rich in CO2. Another option is to have a mixture of algae 
and water flow through a series of horizontal pipes. At first 
the water would be quite clear, with some nutrients added, but 
it would end as a kind of pea soup, which could be pumped 
straight into a factory. The algae would be filtered out so they 
could be processed as fuel.’
Perhaps the water could be recycled and re-used afterwards?
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The use of algae to assist in addressing the biofuels (and animal food) 
problem has merit. However, it hardly scratches the more pressing 
issue of the total overload of Earth as we know it by humans and 
our by-products. Consider that in 1973 the world emitted roughly 
17 billion tons of carbon dioxide from fossil fuels, compared with 30 
billion tons today. The result is a rise in atmospheric CO2 from 325 
parts per million (ppm) in 1973 to 385 ppm today – and increasing 
by 2.4 ppm each year.1 The production of algae to address the huge 
and growing problem on this scale is simply beyond human capacity. 
– J P van Niekerk (Managing Editor)
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Citrus aurantium – beware of the bitter 
orange
To the Editor: The interesting case report regarding a young 
man who presented with a myocardial infarction after the 
use of a synephrine-containing substance1 raises a number of 
issues.
The hypothesis that the infarction might have been caused 
by coronary spasm followed by thrombosis may be supported 
by a similar case of a 28-year-old man who developed a 
myocardial infarct after abusing synephrine tablets.2 Many 
patients use complementary and alternative medicines (CAMs) 
in conjunction with their prescribed medicines – and up to 72% 
of users do not inform their treating physician accordingly.3,4 
With the narrow therapeutic window of many commonly 
used medicines, the potential interactions and adverse effects 
when used with CAMs should not be underestimated. In this 
particular context, Citrus aurantium (Seville or bitter orange) 
is found in a number of foodstuffs, including marmalade, 
beer (Belgian Orange Muscat) and some teas, and in over-
the-counter weight-loss products. In some countries (e.g. 
Iran, Mexico), the dried or ripe fruit form part of local dietary 
traditions.
In addition to the mechanisms mentioned by the authors, 
in which the use of C. aurantium could lead to cardiovascular 
side-effects, is the effect on drug metabolism. C. aurantium, 
grapefruit (C. paradisi) and pomelo (C. maximi) contain a 
number of flavonoids including 6’,7’-dihydroxybergamottin, 
which is used to selectively block the intestinal cytochrome 
P450 isoenzyme, CYP3A4, in bioavailability studies.5 C. 
aurantium also contains a furocoumarin (bergapten) that 
inhibits CYP3A4.6 Since about a quarter of pharmaceuticals are 
metabolised by the CYP3A4 system (e.g. warfarin, felodipine, 
indinavir, simvastatin), and an inhibitory effect on this system 
could lead to increased serum drug levels of drugs metabolised 
by CYP3A4, a great potential for adverse interactions exists.5 
The potential negative interaction of C. aurantium has been 
noted by some drug manufacturers, where its concomitant use 
is contraindicated with agents such as imatinib and nilotinib, 
which are used in the treatment of chronic myeloid leukaemia.
A greater awareness of the potential danger of C. aurantium 
and other CAMs, when used in combination with other drugs, 
should contribute to increased patient safety. We therefore 
believe that it is reasonable to suggest that pharmaceutical 
manufacturers, pharmacists and prescribers take potential 
drug-CAM interactions into account, especially with the 
preparation of package inserts and when writing prescriptions. 
The public should be educated to be aware of the injudicious 
use of CAMs and that not informing their doctors of their use 
could have dire consequences.
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